140 related articles for article (PubMed ID: 19530072)
1. Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux.
Suzuki T; Miyata M; Zaima C; Furuishi T; Fukami T; Kugawa F; Tomono K
J Pharm Sci; 2010 Jan; 99(1):413-21. PubMed ID: 19530072
[TBL] [Abstract][Full Text] [Related]
2. Involvement of an influx transporter in the blood-brain barrier transport of naloxone.
Suzuki T; Ohmuro A; Miyata M; Furuishi T; Hidaka S; Kugawa F; Fukami T; Tomono K
Biopharm Drug Dispos; 2010 May; 31(4):243-52. PubMed ID: 20437463
[TBL] [Abstract][Full Text] [Related]
3. Possible involvement of cationic-drug sensitive transport systems in the blood-to-brain influx and brain-to-blood efflux of amantadine across the blood-brain barrier.
Suzuki T; Fukami T; Tomono K
Biopharm Drug Dispos; 2015 Mar; 36(2):126-37. PubMed ID: 25410756
[TBL] [Abstract][Full Text] [Related]
4. In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method.
Moriki Y; Suzuki T; Furuishi T; Fukami T; Tomono K; Watanabe J
J Drug Target; 2005 Jan; 13(1):53-9. PubMed ID: 15848954
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.
Kanaan M; Daali Y; Dayer P; Desmeules J
Fundam Clin Pharmacol; 2009 Oct; 23(5):543-8. PubMed ID: 19656202
[TBL] [Abstract][Full Text] [Related]
6. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
7. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier.
Suzuki T; Zaima C; Moriki Y; Fukami T; Tomono K
J Drug Target; 2007 Jan; 15(1):67-74. PubMed ID: 17365275
[TBL] [Abstract][Full Text] [Related]
9. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect.
Padowski JM; Pollack GM
Brain Res; 2011 Dec; 1426():1-17. PubMed ID: 22036081
[TBL] [Abstract][Full Text] [Related]
10. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
[TBL] [Abstract][Full Text] [Related]
11. Selective brain to blood efflux transport of para-aminohippuric acid across the blood-brain barrier: in vivo evidence by use of the brain efflux index method.
Kakee A; Terasaki T; Sugiyama Y
J Pharmacol Exp Ther; 1997 Dec; 283(3):1018-25. PubMed ID: 9399971
[TBL] [Abstract][Full Text] [Related]
12. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier.
Kakee A; Takanaga H; Terasaki T; Naito M; Tsuruo T; Sugiyama Y
J Neurochem; 2001 Oct; 79(1):110-8. PubMed ID: 11595763
[TBL] [Abstract][Full Text] [Related]
13. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
15. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE).
Ouyang H; Andersen TE; Chen W; Nofsinger R; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jun; 98(6):2227-36. PubMed ID: 18855917
[TBL] [Abstract][Full Text] [Related]
17. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.
Kusuhara H; Suzuki H; Terasaki T; Kakee A; Lemaire M; Sugiyama Y
J Pharmacol Exp Ther; 1997 Nov; 283(2):574-80. PubMed ID: 9353372
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
Bachmeier CJ; Trickler WJ; Miller DW
Drug Metab Dispos; 2006 Jun; 34(6):998-1003. PubMed ID: 16554372
[TBL] [Abstract][Full Text] [Related]
19. Brain to blood efflux transport of adenosine: blood-brain barrier studies in the rat.
Isakovic AJ; Abbott NJ; Redzic ZB
J Neurochem; 2004 Jul; 90(2):272-86. PubMed ID: 15228584
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2.
Asaba H; Hosoya K; Takanaga H; Ohtsuki S; Tamura E; Takizawa T; Terasaki T
J Neurochem; 2000 Nov; 75(5):1907-16. PubMed ID: 11032880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
